HCN updates MDref, fixes PracSoft bug
The MDref update is current from February 1 and is a differential update that builds on the most recent full build of MDref in December 2011.
It also includes information on Jevtana (cabazitaxel), which was approved by the Therapeutic Goods Administration (TGA) for the treatment, in combination with prednisone or prednisolone, of patients with hormone-refractory metastatic prostate cancer.
There are also new drug monographs and Product Information (PIs) on Trajenta (linagliptin), a dipeptidyl peptidase 4 inhibitor for adult patients with type 2 diabetes to improve glycaemic control, and Vimovo (naproxen and esomeprazole) for patients using NSAIDS for the symptomatic management of rheumatoid and osteoarthritis who have an increased risk of gastrointestinal ulceration.
The February 2012 MDref update for Medical Director users will be delivered via HCN's automatic update. Alternatively, users can download the update manually.
Posted in Australian eHealth